# PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC

> **NCT07630363** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Renal Cell Carcinoma (RCC)
- PTC
- Atorvastatin
- Targeted Therapy Combined With Immunotherapy

## Interventions

- **DRUG:** Axitinib
- **DRUG:** Toripalimab
- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT07630363
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-14
- **Primary completion:** 2028-03-01
- **Final completion:** 2030-04-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07630363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07630363, "PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07630363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*